N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia

Neuroendocrinology Letters

Volumn 33, Issue SUPPL. 2, 2012, Pages 87-92

  Vecka, Marek ^a   Dušejovsḱa, Magdalena ^a   Stakov́a, Barbora ^a   Zeman, Miroslav ^a   Vávrov́a, Lucie ^a   Kodydková, Jana ^a   Slabý, Adolf ^a   Žák, Aleš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Atherogenic dyslipidemia; N 3 PUFA; Residual cardiovascular risk

Indexed keywords

ATORVASTATIN; FATTY ACID; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 ACID ETHYL ESTER; PHOSPHOLIPID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; CONFERENCE PAPER; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIACYLGLYCEROLEMIA; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OXIDATIVE STRESS; RISK FACTOR; TREATMENT DURATION;

EID: 84871093811     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Ahotupa M, Ruutu M, Mäntylä E (1996). Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem. 29: 139-144. (Pubitemid 26115431)
2. Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 23: 469-480.
3. Araki A, Sako Y (1987). Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 422: 43-52. (Pubitemid 17167357)
4. Bays HE, Tighe AP, Sadovsky R, Davidson MH (2008). Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 6: 391-409.
5. Calabresi L, Donati D, Pazzuconi F, Sirtori CR, Franceschini G (2000). Omacor in familial combined hyperlipidemia: Effects on lipids and low-density lipoprotein subclasses. Atherosclerosis 148: 387-396. (Pubitemid 30064470)
6. Carpentier YA, Portois L, Malaisse WJ (2006). N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr. 83: 1499S-1504S. (Pubitemid 44713091)
7. Chan DC, Watts GF, Nguyen MN, Barrett PH (2006a). Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 84: 37-43. (Pubitemid 44699169)
8. Chan DC, Barrett PH, Watts GF (2006b). Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol. 17: 28-36. (Pubitemid 43100300)
9. Chapman MJ, Ginsberg HN, Amarceno P, Andreotti F, Borén J, Catapano AL, et al (2011). Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 32: 1345-1361.
10. Cromwell WC, Otvos JD (2004). Low-density lipoprotein particle numbers and risk for cardiovascular disease. Curr Atheroscler Rep. 6: 381
11. Gazi IF, Filippatos TD, Tsimihodimos V, Saougos VG, Liberopoulos EN, Mikhailidis DP, et al (2006). The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 41: 647-654. (Pubitemid 44547679)
12. Harris WS, Jacobson TA (2009). Omega-3 fatty acids. In: Ballantyne CM. (ed.), Clinical Lipidology: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders Elsevier; pp. 326-338.
13. Heller G (2006). Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis. Stat Med. 25: 2543-2553.
14. James MJ, Ursin VM, Cleland LG (2003). Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr. 77: 1140-1145. (Pubitemid 44858428)
15. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N (2011). (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv. Nutr 2: 304-316.
16. Kremmyda L-S, Tvrzická E, Staňková B, Žák A (2011). Fatty acids as biocompounds: Their role in human metabolism, health and disease - a review. Part 2: Fatty acid physiological roles and applications in human health and disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 155: 195-218.
17. Kodydková J, Vávrová L, Zeman M, Jirák R, Macášek J, Staňková B, et al (2009). Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem. 42: 1368-1374.
18. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al (2002). Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Soprevvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 105: 1897-1903. (Pubitemid 34437615)
19. Nakamura MT, Cheon Y, Li Y, Nara TY (2004). Mechanisms of regulation of gene expression by fatty acids. Lipids 39: 1077-1083. (Pubitemid 40129050)
20. Oravec S, Dukát A, Gavorník P, Lovásová Z, Gruber K (2011). Atherogenic normolipidemia - a new phenomenon in the lipoprotein profile of clinically healthy subjects. Neuro Endocrinol Lett. 32: 317-321.
21. Poudyal H, Panchal SK, Diwan V, Brown L (2011). Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res. 50: 372-387.
22. Robinson JG, Stone NJ (2006). Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 98: 39i-49i.
23. Romanens M, Ackermann F, Spence JD, Darioli R, Rodondi N, Corti R, et al (2010). Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil. 17: 18-23.
24. Schumaker VN, Puppione DL (1986). Sequential flotation ultra-centrifugation. Methods Enzymol. 128: 155-170.
25. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, et al (2010). High pre-β1 HDL concentrations and low lecithin:cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem. 56: 1128-1137.
26. Shapiro H, Theilla M, Attal-Singer J, Singer P (2011). Effects of polyunsaturated fatty acids consumption in diabetic nephropathy. Nat Rev Nephrol. 7: 110-121.
27. Shearer GC, Savinova OV, Harris WS (2012). Fish oil - How does it reduce plasma triglycerides? Biochim Biophys Acta. 1821: 843-851.
28. Soran H, Younis NN, Charlton-Menys V, Durrington P (2009). Variation of paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol. 20: 265-274.
29. Tvrzická E, Vecka M, Staňková B, Žák A (2002). Analysis of fatty acids in plasma lipoproteins by gas chromatography-flame ionisation detection. Quantitative aspects. Anal Chim Acta 465: 337-350.
30. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): A randomized open-label, blinded end-point analysis. Lancet 369: 1090-1098. (Pubitemid 46483662)
31. Yuan G, Al-Shali KZ, Hegele RA (2007). Hypertriglyceridemia: its etiology, effects and treatment. Can Med Assoc J. 176: 1113-1120. (Pubitemid 46649735)
32. Zeman M, Žák A, Vecka M, Tvrzická E, Písaříková A, Staňková B (2006). N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. J Nutr Biochem. 17: 379-384. (Pubitemid 43729351)
33. Zhang B, Menzin J, Friedman M, Korn JR, Burge RT (2008). Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. Curr Med Res Opin. 24: 2711-2717.
34. Žák A, Tvrzická E, Vecka M, Jáchymová M, Duffková L, Staňková B, et al (2007). Severity of metabolic syndrome unfavorably influences oxidative stress and fatty acid metabolism in men.Tohoku J Exp Med. 212: 359-371. (Pubitemid 351565833)